JP2004522747A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004522747A5 JP2004522747A5 JP2002560585A JP2002560585A JP2004522747A5 JP 2004522747 A5 JP2004522747 A5 JP 2004522747A5 JP 2002560585 A JP2002560585 A JP 2002560585A JP 2002560585 A JP2002560585 A JP 2002560585A JP 2004522747 A5 JP2004522747 A5 JP 2004522747A5
- Authority
- JP
- Japan
- Prior art keywords
- acid
- reacted
- formulation
- hydroxyphenyl
- propionate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 12
- 238000009472 formulation Methods 0.000 claims 6
- 239000002253 acid Substances 0.000 claims 3
- 238000000034 method Methods 0.000 claims 3
- MEPHNYCULIJGJE-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid hydroiodide Chemical compound OC(C(F)(F)F)=O.OC(C(F)(F)F)=O.OC(C(F)(F)F)=O.I MEPHNYCULIJGJE-UHFFFAOYSA-N 0.000 claims 2
- VAKOWVVVSGPEFK-UHFFFAOYSA-N 2,2,2-trifluoroacetic acid;hydroiodide Chemical compound I.OC(=O)C(F)(F)F VAKOWVVVSGPEFK-UHFFFAOYSA-N 0.000 claims 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 230000003078 antioxidant effect Effects 0.000 claims 2
- 239000007963 capsule composition Substances 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229910052740 iodine Inorganic materials 0.000 claims 2
- 239000011630 iodine Substances 0.000 claims 2
- 239000007951 isotonicity adjuster Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- NMHMNPHRMNGLLB-UHFFFAOYSA-N phloretic acid Chemical compound OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 claims 2
- 239000007787 solid Substances 0.000 claims 2
- 239000002904 solvent Substances 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 238000011287 therapeutic dose Methods 0.000 claims 2
- -1 3,5-diiodo-4 - hydroxyphenyl Chemical group 0.000 claims 1
- WONYMNWUJVKVII-UHFFFAOYSA-N 3,5-diiodothyropropionic acid Chemical compound IC1=CC(CCC(=O)O)=CC(I)=C1OC1=CC=C(O)C=C1 WONYMNWUJVKVII-UHFFFAOYSA-N 0.000 claims 1
- 206010007559 Cardiac failure congestive Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 1
- 229960000583 acetic acid Drugs 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 239000012362 glacial acetic acid Substances 0.000 claims 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims 1
- 229910000043 hydrogen iodide Inorganic materials 0.000 claims 1
- 239000007943 implant Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000012669 liquid formulation Substances 0.000 claims 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 claims 1
- 235000019260 propionic acid Nutrition 0.000 claims 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims 1
- 239000007858 starting material Substances 0.000 claims 1
- 230000002194 synthesizing effect Effects 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/774,994 US6534676B2 (en) | 2001-01-31 | 2001-01-31 | Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same |
| PCT/US2002/003162 WO2002060389A2 (en) | 2001-01-31 | 2002-01-31 | Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004522747A JP2004522747A (ja) | 2004-07-29 |
| JP2004522747A5 true JP2004522747A5 (enExample) | 2005-12-22 |
Family
ID=25102976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002560585A Pending JP2004522747A (ja) | 2001-01-31 | 2002-01-31 | ３，５−ジヨードチロプロピオン酸を用いた慢性心不全および／または高コレステロールの治療方法と、この酸の製造方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US6534676B2 (enExample) |
| EP (1) | EP1432310A4 (enExample) |
| JP (1) | JP2004522747A (enExample) |
| AU (1) | AU2002243801B2 (enExample) |
| CA (1) | CA2436421C (enExample) |
| MX (1) | MXPA03006855A (enExample) |
| WO (1) | WO2002060389A2 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6716877B2 (en) * | 2001-01-31 | 2004-04-06 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method to treat chronic heart failure and/or elevated cholesterol levels |
| US7504435B2 (en) * | 2001-01-31 | 2009-03-17 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Method for stimulating weight loss and/or for lowering triglycerides in patients |
| US9198887B2 (en) | 2003-09-15 | 2015-12-01 | Nanopharmaceuticals Llc | Thyroid hormone analogs and methods of use |
| US8668926B1 (en) | 2003-09-15 | 2014-03-11 | Shaker A. Mousa | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof |
| AU2004273986B2 (en) * | 2003-09-15 | 2010-04-22 | Nanopharmaceuticals Llc | Thyroid hormone analogs and methods of use in angiogenesis |
| US8071134B2 (en) * | 2003-09-15 | 2011-12-06 | Ordway Research Institute, Inc. | Thyroid hormone analogs and methods of use |
| EP2428516A1 (en) * | 2003-11-19 | 2012-03-14 | Metabasis Therapeutics, Inc. | Novel phosphorus-containing thyromimetics |
| CA2583410A1 (en) * | 2004-09-15 | 2006-03-23 | Albany College Of Pharmacy | Thyroid hormone analogs for promoting angiogenesis |
| US20090232879A1 (en) | 2005-05-26 | 2009-09-17 | Metabasis Therapeutics, Inc. | Thyromimetics for the Treatment of Fatty Liver Diseases |
| RU2007148927A (ru) * | 2005-05-26 | 2009-07-10 | Метабэйзис Терапьютикс, Инк. (Us) | Новые тиреомиметики, содержащие фосфиновую кислоту |
| US20090022806A1 (en) * | 2006-12-22 | 2009-01-22 | Mousa Shaker A | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists and formulations and uses thereof |
| US10130686B2 (en) | 2005-09-15 | 2018-11-20 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating inflammatory disorders |
| US9498536B2 (en) | 2005-09-15 | 2016-11-22 | Nanopharmaceuticals Llc | Method and composition of thyroid hormone analogues and nanoformulations thereof for treating anti-inflammatory disorders |
| WO2007035612A2 (en) | 2005-09-16 | 2007-03-29 | Ordway Research Institute, Inc. | Polyphenol conjugates as rgd-binding compounds and methods of use |
| EP2120913B1 (en) * | 2006-12-22 | 2015-01-21 | NanoPharmaceuticals LLC | Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations and uses thereof |
| AU2008219585A1 (en) * | 2007-02-27 | 2008-09-04 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Administration of 3,5-diiodothyropropionic acid for stimulating weight loss, and/or lowering triglyceride levels, and/or treatment of metabolic syndrome. |
| JPWO2009028608A1 (ja) * | 2007-08-31 | 2010-12-02 | 三菱瓦斯化学株式会社 | オルト位がヨウ素置換されたフェノール誘導体の製造方法 |
| WO2010075332A1 (en) * | 2008-12-23 | 2010-07-01 | Charitable Leadership Foundation | Small molecule ligands of the integrin rgd recognition site and methods of use |
| US9180107B2 (en) * | 2009-03-31 | 2015-11-10 | Nanopharmaceuticals Llc | Combination treatment of cancer with cetuximab and tetrac |
| WO2010148007A2 (en) | 2009-06-17 | 2010-12-23 | Ordway Research Institute, Inc. | Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof |
| US8802240B2 (en) | 2011-01-06 | 2014-08-12 | Nanopharmaceuticals Llc | Uses of formulations of thyroid hormone analogs and nanoparticulate forms thereof to increase chemosensitivity and radiosensitivity in tumor or cancer cells |
| WO2015120458A1 (en) * | 2014-02-10 | 2015-08-13 | Fred Hutchinson Cancer Research Center | Halogen treatment of heart attack and ischemic injury |
| AU2017279536A1 (en) | 2016-06-07 | 2018-12-20 | Nanopharmaceuticals, Llc | Non-cleavable polymer conjugated with αvβ3 integrin thyroid antagonists |
| WO2018094265A2 (en) | 2016-11-21 | 2018-05-24 | Viking Therapeutics, Inc. | Method of treating glycogen storage disease |
| AU2018280118B2 (en) | 2017-06-05 | 2021-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| EA202091979A1 (ru) | 2018-03-22 | 2021-06-22 | Вайкинг Терапьютикс, Инк. | Кристаллические формы и способы получения кристаллических форм соединения |
| US10328043B1 (en) | 2018-04-11 | 2019-06-25 | Nanopharmaceuticals, Llc. | Composition and method for dual targeting in treatment of neuroendocrine tumors |
| US11351137B2 (en) | 2018-04-11 | 2022-06-07 | Nanopharmaceuticals Llc | Composition and method for dual targeting in treatment of neuroendocrine tumors |
| EP4775207A2 (en) | 2018-12-05 | 2026-07-15 | Viking Therapeutics, Inc. | Compositions for the treatment of fibrosis |
| US10961204B1 (en) | 2020-04-29 | 2021-03-30 | Nanopharmaceuticals Llc | Composition of scalable thyrointegrin antagonists with improved blood brain barrier penetration and retention into brain tumors |
| EP4161925A4 (en) | 2020-06-09 | 2024-09-04 | Viking Therapeutics, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER DISEASES |
| US11723888B2 (en) | 2021-12-09 | 2023-08-15 | Nanopharmaceuticals Llc | Polymer conjugated thyrointegrin antagonists |
| JP2025522112A (ja) | 2022-07-11 | 2025-07-10 | プリズム・エルエルシー | アラン・ハーンドン・ダドリー症候群を治療するための方法 |
| CA3261860A1 (en) * | 2022-07-11 | 2024-01-18 | Dexcel Pharma Technologies Ltd. | METHODS AND FORMULATIONS FOR THE PRENATAL TREATMENT OF ALLAN-HERNDON-DUDLEY SYNDROME |
| WO2024015764A1 (en) * | 2022-07-11 | 2024-01-18 | PriZm, LLC | 3,5-diiodothyropropionic acid compositions and methods of use thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US812140A (en) * | 1901-06-14 | 1906-02-06 | Perry E Kent | Gun-barrel for pistols, rifles, and ordnance. |
| US2803654A (en) | 1955-06-24 | 1957-08-20 | Baxter Laboratories Inc | Preparation of thyroxine products |
| DE1078582B (de) * | 1958-10-29 | 1960-03-31 | Hoechst Ag | Verfahren zur Herstellung substituierter Thyropropionsaeuren |
| US3102136A (en) * | 1959-06-24 | 1963-08-27 | Warner Lambert Pharmaceutical | Process of preparing diiodinated analogs of thyronine |
| US3149153A (en) * | 1961-12-05 | 1964-09-15 | Smith Kline French Lab | 3'-substituted-3, 5-diiodothyronine and salts thereof |
| US5158978A (en) | 1990-02-05 | 1992-10-27 | British Technology Group (U.S.A.) | Thyroid hormone treatment of acute cardiovascular compromise |
| US5331000A (en) * | 1992-03-09 | 1994-07-19 | Sepracor Inc. | Antipyretic and analgesic methods and compositions containing optically pure R(-) ketoprofen |
| WO1993017680A1 (en) * | 1992-03-13 | 1993-09-16 | Sepracor, Inc. | Antipyretic and analgesic methods and compositions containing optically pure r-etodolac |
| US5284971A (en) | 1992-07-16 | 1994-02-08 | Syntex (U.S.A.) Inc. | 4-(3-cyclohexyl-4-hydroxy or-methoxy phenylsulfonyl) 3,5 dibromo phenyl acetic thyromimetic cholesterol-lowering agents |
| US5981592A (en) * | 1995-03-13 | 1999-11-09 | Loma Linda University Medical Center | Method and composition for treating cystic fibrosis |
| US5883294A (en) | 1997-06-18 | 1999-03-16 | The Regeants Of The University Of California | Selective thyroid hormone analogs |
-
2001
- 2001-01-31 US US09/774,994 patent/US6534676B2/en not_active Expired - Fee Related
-
2002
- 2002-01-31 JP JP2002560585A patent/JP2004522747A/ja active Pending
- 2002-01-31 AU AU2002243801A patent/AU2002243801B2/en not_active Ceased
- 2002-01-31 CA CA2436421A patent/CA2436421C/en not_active Expired - Fee Related
- 2002-01-31 WO PCT/US2002/003162 patent/WO2002060389A2/en not_active Ceased
- 2002-01-31 EP EP02709310A patent/EP1432310A4/en not_active Withdrawn
- 2002-01-31 MX MXPA03006855A patent/MXPA03006855A/es active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2436421A1 (en) | Method to treat chronic heart failure and/or elevated cholesterol levels using 3,5-diiodothyropropionic acid and method to prepare same | |
| US7767229B1 (en) | Use of poly diallyamine polymers | |
| CN105820107B (zh) | 具有快速皮肤和生物膜穿透速度的非甾体抗炎药的前药及其新的医药用途 | |
| JP4740524B2 (ja) | 熱応答粘膜接着性医薬−担体組成物 | |
| JP4542743B2 (ja) | ピリドン誘導体の溶液状医薬組成物 | |
| JP4544859B2 (ja) | 男性勃起機能不全の治療のためのプロスタグランジン組成物 | |
| CN102159196B (zh) | 治疗上消化道用的药用制剂 | |
| US12128027B2 (en) | N—N-dimethyltryptamine (DMT) and DMT analog compositions, methods of making, and methods of use thereof | |
| JP2004534057A5 (enExample) | ||
| JP3411690B2 (ja) | 局所投与用アレンドロン酸ナトリウム製剤 | |
| JP2004510816A (ja) | モダフィニル化合物の製薬学的溶液 | |
| JP2005513014A5 (enExample) | ||
| JP2006514665A5 (enExample) | ||
| EP2158908B1 (en) | Composition for transdermal administration | |
| CN103110609A (zh) | 一种治疗口腔溃疡的涂膜剂及其制备方法 | |
| JP5997658B2 (ja) | 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用 | |
| CN102552140B (zh) | 罗格列酮的液体组合物 | |
| JPH05271226A (ja) | 創傷治癒促進剤 | |
| JP6621775B2 (ja) | 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用 | |
| JP2022125076A (ja) | 非常に速い皮膚及び膜浸透速度を有するｎｓａｉａプロドラッグ及びその新規医薬使用 | |
| HK40091513A (en) | Pro-drugs of nsaias with very high skin and membranes penetration rates and their new medicinal uses | |
| JPH0476970B2 (enExample) | ||
| Sanger et al. | ACUTE POSTOPERATIVE CARDIORESPIRATORY INSUFFICIENCY: TREATMENT BY CURARIZATION AND ARTIFICIAL BREATHING | |
| HK1221467A1 (zh) | 具有快速皮肤和生物膜穿透速度的非甾体抗炎药的前药及其新的医药用途 | |
| JPH06247857A (ja) | 坐剤組成物 |